152 related articles for article (PubMed ID: 35318970)
1. Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years.
Jurkiewicz E; Tsvetkova S; Grinberg A; Pasquiers B
Invest Radiol; 2022 Aug; 57(8):510-516. PubMed ID: 35318970
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclenol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study).
Hao J; Bourrinet P; Desché P
Invest Radiol; 2019 Jul; 54(7):396-402. PubMed ID: 30870257
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body.
Hao J; Pitrou C; Bourrinet P
Invest Radiol; 2024 Feb; 59(2):124-130. PubMed ID: 37812485
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function.
Bradu A; Penescu M; Pitrou C; Hao J; Bourrinet P
Invest Radiol; 2021 Aug; 56(8):486-493. PubMed ID: 34197356
[TBL] [Abstract][Full Text] [Related]
5. Dose Finding Study of Gadopiclenol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System.
Bendszus M; Roberts D; Kolumban B; Meza JA; Bereczki D; San-Juan D; Liu BP; Anzalone N; Maravilla K
Invest Radiol; 2020 Mar; 55(3):129-137. PubMed ID: 31917762
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA; Kolumban B; Hutóczki G; Dziadziuszko K; Bereczki D; Bago A; Pichiecchio A
Invest Radiol; 2023 May; 58(5):307-313. PubMed ID: 36729404
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity.
Robic C; Port M; Rousseaux O; Louguet S; Fretellier N; Catoen S; Factor C; Le Greneur S; Medina C; Bourrinet P; Raynal I; Idée JM; Corot C
Invest Radiol; 2019 Aug; 54(8):475-484. PubMed ID: 30973459
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
9. Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine.
Violas X; Rasschaert M; Santus R; Factor C; Corot C; Catoen S; Idée JM; Robert P
Invest Radiol; 2022 Feb; 57(2):130-139. PubMed ID: 34411032
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Safety Assessment of Gadopiclenol: A High-Relaxivity Macrocyclic Gadolinium-Based MRI Contrast Agent.
Gendron C; Bourrinet P; Dencausse A; Fretellier N
Invest Radiol; 2024 Feb; 59(2):108-123. PubMed ID: 37921752
[TBL] [Abstract][Full Text] [Related]
11. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Gadopiclenol and P846, 2 High-Relaxivity Macrocyclic Magnetic Resonance Contrast Agents Without Protein Binding, in a Rodent Model of Hepatic Metastases: Potential Solutions for Improved Enhancement at Ultrahigh Field Strength.
Fries P; Massmann A; Robert P; Corot C; Laschke MW; Schneider G; Buecker A; Müller A
Invest Radiol; 2019 Sep; 54(9):549-558. PubMed ID: 31033675
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
[TBL] [Abstract][Full Text] [Related]
15. Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.
Fretellier N; Rasschaert M; Bocanegra J; Robert P; Factor C; Seron A; Idée JM; Corot C
Invest Radiol; 2021 Dec; 56(12):826-836. PubMed ID: 34091462
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults.
Hofmann BM; Riecke K; Klein S; Berse M; Rottmann A; Sutter G; Ebert W
Invest Radiol; 2024 Feb; 59(2):140-149. PubMed ID: 37921759
[TBL] [Abstract][Full Text] [Related]
18. Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide.
Funke SKI; Factor C; Rasschaert M; Lezius L; Sperling M; Karst U; Robert P
Radiology; 2022 Oct; 305(1):179-189. PubMed ID: 35727155
[TBL] [Abstract][Full Text] [Related]
19. Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent.
Alsogati E; Ghandourah H; Bakhsh A
Cureus; 2023 Aug; 15(8):e43055. PubMed ID: 37680433
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent.
Lohrke J; Berger M; Frenzel T; Hilger CS; Jost G; Panknin O; Bauser M; Ebert W; Pietsch H
Invest Radiol; 2022 Oct; 57(10):629-638. PubMed ID: 35703267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
